Literature DB >> 18620479

In vivo maturation of scaffold-free engineered articular cartilage on hydroxyapatite.

Sota Kitahara1, Koichi Nakagawa, Robert L Sah, Yuichi Wada, Tetsuro Ogawa, Hideshige Moriya, Koichi Masuda.   

Abstract

Tissue engineering is a promising approach, not only for cartilage, but also for osteochondral repair. Recent studies have demonstrated that scaffold-free cartilaginous tissue can be engineered using the alginate-recovered-chondrocyte (ARC) method. This method has also been applied to form osteochondral tissue using bovine articular chondrocytes and coralline hydroxyapatite (HA). The purpose of this study was to test whether osteochondral tissue, fabricated in vitro using the ARC method combined with a block of HA, would undergo maturation in vivo using a subcutaneous model in immunodeficient mice. Articular chondrocytes were isolated from the cartilage of New Zealand white rabbits and cultured in alginate beads. The cells with their associated matrix were recovered by dissolving the alginate beads with a sodium citrate buffer, resuspended in media and seeded onto a porous HA block. After 4 weeks of culture, some samples were analyzed, and others were implanted into subcutaneous pockets in nude mice. The analysis involved removing the cartilage portion of the de novo-formed ARC-HA graft and performing biochemical and histological examinations. Some samples were subjected to nondecalcified histology. Histological and immunohistochemical analyses of cartilaginous tissue were performed at 0, 2, 4, and 8 weeks after implantation. Biochemical characteristics were examined at 0, 4, and 8 weeks. The size and shape of the implanted ARC osteochondral tissue changed with time. The histological and immunohistochemical examination of the tissue revealed that it contained a cartilage-like matrix that stained strongly with Toluidine blue and for collagen type II. The proteoglycan (PG) content had increased significantly at 4 weeks from baseline. However, by 8 weeks, the PG content had decreased from 4 weeks. The results presented here represent a possible approach to form a tissue-engineered osteochondral implant. Further studies are needed to improve biomechanical properties of the osteochondral implant to be suitable for surgical transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620479     DOI: 10.1089/ten.tea.2006.0419

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  6 in total

1.  In vivo implantation of tissue-engineered human nasal septal neocartilage constructs: a pilot study.

Authors:  Angela A Chang; Marsha S Reuther; Kristen K Briggs; Barbara L Schumacher; Gregory M Williams; Maripat Corr; Robert L Sah; Deborah Watson
Journal:  Otolaryngol Head Neck Surg       Date:  2011-10-26       Impact factor: 3.497

2.  The elusive path to cartilage regeneration.

Authors:  Ernst B Hunziker
Journal:  Adv Mater       Date:  2009-09-04       Impact factor: 30.849

3.  Scaffold-free cartilage subjected to frictional shear stress demonstrates damage by cracking and surface peeling.

Authors:  G Adam Whitney; Karthik Jayaraman; James E Dennis; Joseph M Mansour
Journal:  J Tissue Eng Regen Med       Date:  2014-06-26       Impact factor: 3.963

Review 4.  Osteochondral tissue engineering: scaffolds, stem cells and applications.

Authors:  Patcharakamon Nooeaid; Vehid Salih; Justus P Beier; Aldo R Boccaccini
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

5.  Methods for producing scaffold-free engineered cartilage sheets from auricular and articular chondrocyte cell sources and attachment to porous tantalum.

Authors:  G Adam Whitney; Hisashi Mera; Mark Weidenbecher; Amad Awadallah; Joseph M Mansour; James E Dennis
Journal:  Biores Open Access       Date:  2012-08

6.  Engineering large, anatomically shaped osteochondral constructs with robust interfacial shear properties.

Authors:  Wendy E Brown; Brian J Huang; Jerry C Hu; Kyriacos A Athanasiou
Journal:  NPJ Regen Med       Date:  2021-08-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.